Citations Appearing in 2005

  1. Anderson, K.E. and M. Hojbjerre. A population-based Bayesian approach to the minimal model of glucose and insulin homeostasis. Statistics in Medicine 24(15):2381-2400, 2005.
  2. Arnold, R.D., D.E. Mager, J.E. Slack and R.M. Straubinger. Effect of repetitive administration of doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clinical Cancer Research 11(24):8856-8865, 2005.
  3. Baek, M. and M. Weiss. Down-regulation of Na+ pump alpha(2) isoform in isoprenaline-induced cardiac hypertrophy in rat: Evidence for increased receptor binding affinity but reduced inotropic potency of digoxin. Journal of Pharmacology And Experimental Therapeutics 313(2):731-739, 2005.
  4. Baek, M. and M. Weiss. Mechanism-based modeling of reduced inotropic responsiveness to digoxin in endotoxemic rat hearts. European Journal of Pharmacology 514(1):43-51, 2005.
  5. Bauer, K.S., J.E. Karp, T.S. Garimella, S.L. Wu, M. Tan and D.D. Ross. A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. Leukemia Research 29(3):263-271, 2005.
  6. Berg S.L., L. Bomgaars, C. Twist, K. Matthay, T. Moore and D. Wypij . Impact of body composition on pharmacokinetics of doxorubicin in pediatric patients: A Glaser Pediatric Research Network study. Journal of Clinical Oncology 23(16S) 8519, 2005.
  7. Berg, S.L., P.L. Bonate, J.G. Nuchtern, R. Dauser, L. McGuggey, B. Bernacky and S.M. Blaney. Plasma and cerebrospinal fluid phaymacokinetics of clofarabine in nonhuman primates. Clinical Cancer Research 11(16):5981-5983, 2005.
  8. Beringer, P., K.M.T. Huynh, J. Kriengkauykiat, L. Bo, N. Hoem, S. Louie, E. Han, T. Nguyen, D. Hsu, P. A. Rao, B. Shapiro and M. Gill. Absolute Bioavailability and Intracellular Pharmacokinetics of Azithromycin in Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy 49(4 12):5013-5017, 2005.
  9. Bhasi, K., A. Forrest and Ramanathan. SPLINDID: a semi-parametric, model-based method for obtaining transcription rates and gene regulation parameters from genomic and proteomic expression profiles. Bioinformatics 21(20):3873-3879, 2005.
  10. Blumer, J.L., M.D. Reed, E.L. Kaplan and G.L. Drusano. Explaining the poor bacteriologic eradication rate of single-dose ceftriaxone in group A streptococcal tonsillopharyngitis: A reverse engineering solution using pharmacodynamic modeling. Pediatrics 116(4):927-932, 2005.
  11. Buelga, D.S., M.D.F. de Gatta, E.V. Herrera, A. Dominguez-Gil and M.J. Garcia. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrobial Agents and Chemotherapy 49(12):4934-4941, 2005.
  12. Chadwick, E.G., J.H. Rodman, P. Britto, C. Powell, P. Palumbo, K. Luzuriaga, M. Hughes, E.J. Abrams, P.M. Flynn, W. Borkowsky and R. Yogev. Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. Pediatric Infectious Disease Journal 24(9):793-800, 2005.
  13. Chakraborty, A., S. Yeung, N.A. Pyszczynski and W.J. Jusko. Pharmacodynamic interactions between recombinant mouse interleukin-10 and prednisolone using a mouse endotoxemia model. Journal of Pharmaceutical Sciences 94(3):590-603, 2005.
  14. Chen, J., S. Wang, X.B. Jia, S. Bajimaya, H.M. Lin, V.H. Tam and M. Hu. Disposition of flavonoids via recycling: Comparison of intestinal versus hepatic disposition. Drug Metabolism and Disposition 33(12):1777-1784, 2005.
  15. Davis, G.L., D.R. Nelson, N. Terrault, T.L. Pruett, T.D. Schiano, C.V. Fletcher, C.V. Sapan, L.N. Riser, Y.F. Li, R.J. Whitley and J.W. Gnann. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transplantation 11(8):941-949, 2005.
  16. Daw, N.C., W.L. Furman, C.F. Stewart, L.C. Iacono, M. Krailo, M.L. Bernstein, J.E. Dancey, R.A. Speights, S.M. Blaney, J.M. Croop, G.H. Reaman and P.C. Adamson. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: A children’s oncology group study. Journal of Clinical Oncology 23(25):6172-6180, 2005.
  17. Eiseman, J.L., J. Lan, T.F. Lagattuta, D.R. Hamburger, E. Joseph, J.M. Covey and M.J. Egorin, MJ. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemotherapy and Pharmacology 55(1):21-32, 2005.
  18. Figg W.D., Y. Liu, P. Arlen, J. Gulley, S.M. Steinberg, D.J. Liewehr, M.C. Cox, S. Zhai, S. Cremers, A. Parr, X. Yang, C.C. Chen, E. Jones and W.L. Dahut. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. Journal of Urology 173(3):790-796, 2005.
  19. Fakih, M.G., P.J. Creaven, N. Ramnath, D. Trump, M. Javle, S. Strychor, T.V. Repinski, B.A. Zamboni, J.K. Schwarz, R.A. French and W.C. Zamboni. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors. Clinical Cancer Research 11(16):5942-5949, 2005.
  20. Fischell, T.A., A. Maheshwari, R.A. Mirza, S. Haller, A.J. Carter and J.J. Popma. Impact of frame selection on quantitative coronary angiographic analysis after coronary stenting. Catheterization and Cardiovascular Interventions 64(4):460-467, 2005.
  21. Florian, J.A. Eiseman and R.S. Parker. Accounting for quiescent cells in tumour growth and cancer treatment. IEEE Proceedings Systems Biology 152(4):185-192, 2005.
  22. Fracasso, P.M., K.A. Blum, M.K. Ma, B.R. Tan, L.P. Wright, S.A. Goodner, C.L. Fears, W. Hou, M.A. Arquette, J. Picus, A. Denes, J.E. Mortimer, L. Ratner, s.P. Ivy and H.L. McLeod. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. British Journal of Cancer 93(1):46-53, 2005.
  23. Freeman, B.B. III, P. Hinds, L.C. Iacono, B.I. Razzouk, E.Burghen and C.F. Stewart. Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer. Pediatric Blood and Cancer 2005:10.1002/pbc.20685, 2005.
  24. Garcia, A.A., M. Pujari, S. Jeffers, S. Iqbal, H.J. Lenz, P. Beringer and S. Louie. Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule. Cancer Chemotherapy and Pharmacology 56(1):75-82, 2005.
  25. Getman, K.E. and J.P. Balthasar. Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. Journal of Pharmaceutical Sciences 94(4):718-729, 2005.
  26. Gillenwater, H.H., J.S. McCune, C. Lindley, S. Faucette, S. Shord, A. Donahue, M.A. Socinski, C.F. Stewart, W.C. Zamboni, M.N. Kirstein and D. Moore. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with carboplatin and etoposide in extensive stage small cell lung cancer. Cancer Investigation 23(6):511-519, 2005.
  27. Graham, G., I. Gueorguieva and K. Dickens. A program for the optimum design of pharmacokinetic, pharmacodynamic, drug metabolism and drug-drug interaction models. Computer Methods and Programs in Biomedicine 78(3):237-249, 2005.
  28. Groninger, E., T. Meeuwsen-de Boer, P. Koopmans, D. Uges, W. Sluiter, A. Veerman, W. Kamps and S. de Graaf. Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG). European Journal of Cancer 41(1):98-103, 2005.
  29. Gruwez, B., A. Dauphin and M. Tod. A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol. Journal of Pharmacokinetics and Pharmacodynamics 32(6-May):663-683, 2005.
  30. Gumbo, T., A. Louie, M.R. Deziel and G.L. Drusano. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrobial Agents and Chemotherapy 49(8):3178-3181, 2005.
  31. Heptulla R.A., L.M. Rodriguez, L. Bomgaars and M.W. Haymond. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes 54(4):1100-1107, 2005.
  32. Holleran, J.L., R.A. Parise, E. Joseph, J.L. Eiseman, J.M. Covey, E.R. Glaze, A.V. Lyubimov, Y.F. Chen, D. D’Argenio and M.J. Egorin. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clinical Cancer Research 11(10):3862-3868, 2005.
  33. Hope, W.W., P.A. Warn, A. Sharp, P. Reed, B. Keevil, A. Louie, D.W. Denning and G.L. Drusano. Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis. Journal of Infectious Diseases 192(4):673-680, 2005.
  34. Horton, T.M., S.M. Blaney, A.M. Langevin, J. Kuhn, B. Kamen, S.L. Berg, M. Bernstein and S. Weitman. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: A pediatric oncology group study. Clinical Cancer Research 11(5):1884-1889, 2005.
  35. Hu, K. and M.E. Morris. Pharmacokinetics of -naphthyl isothiocyanate in rats. Journal of Pharmaceutical Sciences 94(11):2441-2451, 2005.
  36. Jeong, E.J., Y. Liu, H.M. Lin and M. Hu. Species- and disposition model-dependent metabolism of raloxifene in gut and liver: Role of UGT1A10. Drug Metabolism and Disposition 33(6):785-794, 2005.
  37. Ji, S.L., Y. Kuo and M.E. Morris. Pharmacokinetics of dietary phenethyl isothiocyanate in rats. Pharmaceutical Research 22(10):1658-1666, 2005.
  38. Ji, S.L., Y.Z. Zeng, P. Wu and E.J.D. Lee. Sampling schedule design towards optimal drug monitoring for individualizing therapy. Computer Methods and Programs in Biomedicine 80(1):57-63, 2005.
  39. Kager, L., M. Cheok, W. Yang, G. Zaza, Q. Cheng, J.C. Panetta, C.H. Pui, J.R. Downing, M.V. Relling and W.E. Evans. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. Journal of Clinical Investigation 115(1):111-117, 2005.
  40. Kenanova, V., T. Olafsen, D.M. Crow, G Sundaresan, M. Subbarayan, N.H. Carter, D.N. Ikle, P.J. Yazaki, A.F. Chatziioannou, S.S. Gambhir, L.E. Williams, J.E. Shively, D. Colcher, A.A. Raubitschek and A.M. Wu. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Research 65(2):622-631, 2005.
  41. Kirstein, M.N., J.C. Panetta, A. Gajjar, G. Nair, L.C. Iacono, B.B. Freeman and C.F. Stewart. Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC. Cancer Chemotherapy and Pharmacology 55(5):433-438, 2005.
  42. Krzyzanski, W., W.J. Jusko, M.C. Wacholtz, N. Minton and Cheung. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. European Journal of Pharmaceutical Sciences 26(3-4):295-306, 2005.
  43. Lagneau, F., J. Marty, P. Beyne and M. Tod. Physiological modeling for indirect evaluation of drug tissular pharmacokinetics under non-steady-state conditions: An example of antimicrobial prophylaxis during liver surgery. Journal of Pharmacokinetics and Pharmacodynamics 32(1):1-32, 2005.
  44. Lomaestro, B.M. and G.L. Drusano. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrobial Agents and Chemotherapy 49(1):461-463, 2005.
  45. Louie, A., M. Deziel, W.G. Liu, M.F Drusano, T. Gumbo and G.L. Drusano. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: Importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrobial Agents and Chemotherapy 49(12):5058-5068, 2005.
  46. Mager, D.E. and W. Krzyzanski. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharmaceutical Research 22(10):1589-1596, 2005.
  47. Mager, D.E., B. Neuteboom and W.J. Jusko. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Pharmaceutical Research 22(1):58-61, 2005.
  48. Marier, J.F., K.G. Chen, P. Prince, G. Scott, J.R.E. del Castillo and P. Vachon. Production of ex vivo lipopolysaccharide-induced tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 is suppressed by trans-resveratrol in a concentration-dependent manner. Canadian Journal of Veterinary Research-Revue Canadienne De Recherche Veterinaire 69(2):151-154, 2005.
  49. Meibohm, B., S. Laer, J.C. Panetta and J.S. Barrett. Population pharmacokinetic studies in pediatrics: Issues in design and analysis. AAPS Journal 7(2), 2005.
  50. Morton, C.L., L. Iacono, J.L. Hyatt, K.R. Taylor, P.J. Cheshire, P.J. Houghton, M.K. Danks, C.F. Stewart and P.M. Potter. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemotherapy and Pharmacology 56(6):629-636, 2005.
  51. Na-Bangchang, K., C. Manyando, R. Ruengweerayut, D. Kioy, M. Mulenga, G.B. Miller and J. Konsil. The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. European Journal of Clinical Pharmacology 61(8):573-582, 2005.
  52. Ng, C.M., A. Joshi, R.L. Dedrick, M.R. Garovoy R.J. Bauer. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharmaceutical Research 22(7):1088-1100, 2005.
  53. Olafsen, T., V.E. Kenanova, G. Sundaresan, A.L. Anderson, D. Crow, P.J. Yazaki, L. Li, M.F. Press, L.E. Williams, J.Y.C. Wong, A.A. Raubitschek, J.E. Shively and A.M. Wu. Optimizing radiolabeled engineered anti-p185(HER2) antibody fragments for in vivo imaging. Cancer Research 65(13):5907-5916, 2005.
  54. Ostergaard, D., J. Viby-Mogensen, S.N. Rasmussen, M.R. Gatke and F. Varin. Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically homozygous for the atypical plasma cholinesterase variant – Effect of injection of human cholinesterase. Anesthesiology 102(6):1124-1132, 2005.
  55. Overholser, B.R., M.B. Kays, S. Lagvankar, M. Goldman, B.A. Mueller and K.M. Sowinski. Pharmacokinetics of intravenously administered levofloxacin in men and women. Pharmacotherapy 25(10):1310-1318, 2005.
  56. Pinto, P.C. and L.M. Rodrigues. Influence of the time of occlusion on the quantitative parameters obtained by modelling trans-epidermal water loss curves to describe the human cutaneous barrier functionin vivo. Medical and Biological Engineering and Computing 43(6):771-775, 2005.
  57. Posey J.A. III, M.W. Saif, R. Carlisle, A. Goetz, J. Rizzo, S. Stevenson, M.S. Rudoltz, J. Kwiatek, P. Simmons, E.K. Rowinsky, C.H. Takimoto and A.W. Tolcher. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas. Clinical Cancer Research 11(21):7866-7871, 2005.
  58. Posey, J.A., H. Wang, J. Hamilton, A. Delgrosso, R.W. Zhang, T. Freda and W.C. Zamboni. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology 56(2):182-188, 2005.
  59. Ramanathan, R.K., S. Ramalingam, M.J. Egorin, C.P. Belani, D.M. Potter, M.Fakih, L.L. Jung, S.Strychor, S.A. Jacobs, D.M. Friedland, D.M. Shin, G.S. Chatta, S. Tutchko and W.C. Zamboni. Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology 55(4):354-360, 2005.
  60. Roy, A. and E.I. Ette. A pragmatic approach to the design of population pharmacokinetic studies. American Association of Pharmaceutical Scientists Journal 7(2):408-420, 2005.
  61. Samtani, M.N. and W.J. Jusko. Stability of dexamethasone sodium phosphate in rat plasma. International Journal of Pharmaceutics 301(1-2):262-266, 2005.
  62. Samtani, M.N., M. Lohle, A. Grant, P.W. Nathanielsz and W.J. Jusko. Betamethasone pharmacokinetics after two prodrug formulations in sheep: Implications for antenatal corticosteroid use. Drug Metabolism and Disposition 33(8):1124-1130, 2005.
  63. Santana, V.M., W.L. Furman, C.A. Billups, F. Hoffer, A.M. Davidoff, P.J. Houghton and C.F. Stewart. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. Journal of Clinical Oncology 23(18):4039-4047, 2005.
  64. Tam, V.H., A. Louie, M.R. Deziel, W.G. Liu, R. Leary and G.L. Drusano. Bacterial-population responses to drug-selective pressure: Examination of garenoxacin’s effect on Pseudomonas aeruginosa. Journal of Infectious Diseases 192(3):420-428, 2005.
  65. Tam, V.H., A.N. Schilling, S. Neshat, K. Poole, D.A. Melnick and E.A. Coyle. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 49(12):4920-4927, 2005.
  66. Tam, V.H., A.N. Schilling and M. Nikolaou. Modelling time-kill studies to discern the pharmacodynamics of meropenem. Journal of Antimicrobial Chemotherapy 55(5):699-706, 2005.
  67. Tam, V.H., A.N. Schilling, G. Vo, S. Kabbara, A.L. Kwa, N.P. Wiederhold and R.E. Lewis. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 49(9):3624-3630, 2005.
  68. ten Tije, A.J., J. Verweij, M.A. Carducci, W. Graveland, T. Rogers, T. Pronk, M.P. Verbruggen, F. Dawkins and S.D. Baker. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. Journal of Clinical Oncology 23(6):1070-1077, 2005.
  69. Walker, P., M.N. Neuhauser, V.H. Tam, J.S. Willey, J.L. Palmer, E. Bruera and R.A. Prince. Subcutaneous administration of cefepime. Journal of Pain and Symptom Management 30(2):170-174, 2005.
  70. Wetzler, M., J. Earp, M.T. Brady, M.K. Keng, S.H. Lee and W.J. Jusko. Synergistic effects of arsenic trioxide and heat shock protein 90 inhibitors on down-regulating signal transducer and activator of transcription protein 3 activity in HEL cells. AACR Meeting Abstracts 46(1):1299, 2005.
  71. Zamboni, W.C., L.L. Jung, M.J. Egorin, D.R. Hamburger, E. Joseph, R.Z. Jin, S. Strychor, R.K. Ramanathan and J.L. Eiseman. Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts. Clinical Cancer Research 11(13):4867-4874, 2005.
  72. Zheng, Z.B., G.Z. Zhu, H. Tak, E. Joseph, J.L. Eiseman and D.J. Creighton. N-(2-hydroxypropyl)methaerylamide copolymers of a glutathione (GSH)-activated glyoxalase I inhibitor and DNA alkylating agent: Synthesis, reaction kinetics with GSH, and in vitro antitumor activities. Bioconjugate Chemistry 16(3):598-607, 2005.
  73. Zhou, X.F., J. MacDiarmid, R.A. Coburn and M.E. Morris. Pharmacokinetics and bioavailability of a newly synthesized dihydropyridine compound with multidrug resistance reversal activity. Biopharmaceutics and Drug Disposition 26(7):279-285, 2005.